Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions.
Identifieur interne : 001431 ( PubMed/Corpus ); précédent : 001430; suivant : 001432Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions.
Auteurs : F. Tison ; J. Lecaroz ; L. Letenneur ; J F DartiguesSource :
- Clinical neuropharmacology [ 0362-5664 ]
English descriptors
- KwdEn :
- Academies and Institutes, Aged, Aged, 80 and over, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Cognition (drug effects), Cross-Sectional Studies, Humans, Motor Activity (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Risk Factors.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- chemical , therapeutic use : Antipsychotic Agents.
- drug effects : Cognition, Motor Activity.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Academies and Institutes, Aged, Aged, 80 and over, Cross-Sectional Studies, Humans, Risk Factors.
Abstract
Three-hundred fifty-two randomly selected residents, aged over 65 years, of 42 representative long-term care institutions in a defined geographic area of south-western France, were assessed for demographic characteristics, drug intake, and motor and cognitive status. Neuroleptic drug intake is described and demographic variables and motor and cognitive status are analyzed according to exposure to neuroleptics and presence of parkinsonism. Exposure to neuroleptics was considered as a "risk factor" for parkinsonism, and the risk (proportion) of parkinsonism attributable to neuroleptics calculated. Twenty-one percent of subjects were exposed to neuroleptics, of whom 27% took more than one. Subjects taking neuroleptics were significantly younger and more cognitively impaired. About 30% of subjects taking neuroleptics had parkinsonism (6.25% of the sample). Postural and action tremors were more frequent than resting tremor, and asymmetry of parkinsonian signs was found in 25%. The mean dosage taken by exposed subjects with parkinsonism was found to be twice that of those without. The proportion of cases of parkinsonism attributable to neuroleptics in institutions was 19%. Our results clearly show that neuroleptic drug use in institutionalized elderly persons is associated with a high risk for parkinsonism.
PubMed: 10047927
Links to Exploration step
pubmed:10047927Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions.</title><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name><affiliation><nlm:affiliation>Département de Neurologie, Hôpital Pellegrin, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lecaroz, J" sort="Lecaroz, J" uniqKey="Lecaroz J" first="J" last="Lecaroz">J. Lecaroz</name></author><author><name sortKey="Letenneur, L" sort="Letenneur, L" uniqKey="Letenneur L" first="L" last="Letenneur">L. Letenneur</name></author><author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J F" last="Dartigues">J F Dartigues</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1999 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:10047927</idno><idno type="pmid">10047927</idno><idno type="wicri:Area/PubMed/Corpus">001431</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001431</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions.</title><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name><affiliation><nlm:affiliation>Département de Neurologie, Hôpital Pellegrin, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lecaroz, J" sort="Lecaroz, J" uniqKey="Lecaroz J" first="J" last="Lecaroz">J. Lecaroz</name></author><author><name sortKey="Letenneur, L" sort="Letenneur, L" uniqKey="Letenneur L" first="L" last="Letenneur">L. Letenneur</name></author><author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J F" last="Dartigues">J F Dartigues</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Academies and Institutes</term><term>Aged</term><term>Aged, 80 and over</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Cognition (drug effects)</term><term>Cross-Sectional Studies</term><term>Humans</term><term>Motor Activity (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cognition</term><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Academies and Institutes</term><term>Aged</term><term>Aged, 80 and over</term><term>Cross-Sectional Studies</term><term>Humans</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Three-hundred fifty-two randomly selected residents, aged over 65 years, of 42 representative long-term care institutions in a defined geographic area of south-western France, were assessed for demographic characteristics, drug intake, and motor and cognitive status. Neuroleptic drug intake is described and demographic variables and motor and cognitive status are analyzed according to exposure to neuroleptics and presence of parkinsonism. Exposure to neuroleptics was considered as a "risk factor" for parkinsonism, and the risk (proportion) of parkinsonism attributable to neuroleptics calculated. Twenty-one percent of subjects were exposed to neuroleptics, of whom 27% took more than one. Subjects taking neuroleptics were significantly younger and more cognitively impaired. About 30% of subjects taking neuroleptics had parkinsonism (6.25% of the sample). Postural and action tremors were more frequent than resting tremor, and asymmetry of parkinsonian signs was found in 25%. The mean dosage taken by exposed subjects with parkinsonism was found to be twice that of those without. The proportion of cases of parkinsonism attributable to neuroleptics in institutions was 19%. Our results clearly show that neuroleptic drug use in institutionalized elderly persons is associated with a high risk for parkinsonism.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10047927</PMID><DateCreated><Year>1999</Year><Month>05</Month><Day>28</Day></DateCreated><DateCompleted><Year>1999</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>1</Issue><PubDate><MedlineDate>1999 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions.</ArticleTitle><Pagination><MedlinePgn>5-10</MedlinePgn></Pagination><Abstract><AbstractText>Three-hundred fifty-two randomly selected residents, aged over 65 years, of 42 representative long-term care institutions in a defined geographic area of south-western France, were assessed for demographic characteristics, drug intake, and motor and cognitive status. Neuroleptic drug intake is described and demographic variables and motor and cognitive status are analyzed according to exposure to neuroleptics and presence of parkinsonism. Exposure to neuroleptics was considered as a "risk factor" for parkinsonism, and the risk (proportion) of parkinsonism attributable to neuroleptics calculated. Twenty-one percent of subjects were exposed to neuroleptics, of whom 27% took more than one. Subjects taking neuroleptics were significantly younger and more cognitively impaired. About 30% of subjects taking neuroleptics had parkinsonism (6.25% of the sample). Postural and action tremors were more frequent than resting tremor, and asymmetry of parkinsonian signs was found in 25%. The mean dosage taken by exposed subjects with parkinsonism was found to be twice that of those without. The proportion of cases of parkinsonism attributable to neuroleptics in institutions was 19%. Our results clearly show that neuroleptic drug use in institutionalized elderly persons is associated with a high risk for parkinsonism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tison</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département de Neurologie, Hôpital Pellegrin, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecaroz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Letenneur</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000047" MajorTopicYN="N">Academies and Institutes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10047927</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001431 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001431 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10047927
|texte= Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10047927" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |